

Report of IRB Review

Project No.	2013-058	Protocol No.	N/A
Version No.	Version 1.0		
Protocol Title	A Blinded Clinical Trial Comparing the Efficacy and Tolerability of Picolight(fixed split dose regimen) for Colonoscopy		
PI	Name	Koon Hee Han	Division Gastroenterology
Sponsor	(CEO / Director general)		
Classification	<input type="checkbox"/> Embryo Production <input type="checkbox"/> Embryo Research <input type="checkbox"/> DNA Test <input type="checkbox"/> Genetic Study <input type="checkbox"/> DNA Bank <input type="checkbox"/> Gene Therapy <input type="checkbox"/> Somatic Cell Embryo Clones		
	<input type="checkbox"/> Case-series study using medical records <input checked="" type="checkbox"/> Surveys <input type="checkbox"/> Research using biological samples (<input type="checkbox"/> Stored Samples <input type="checkbox"/> Collecting new samples)		
	<input type="checkbox"/> Drugs <input type="checkbox"/> Devices <input type="checkbox"/> Procedures <input type="checkbox"/> Others		
Phase	<input type="checkbox"/> Phase I <input type="checkbox"/> Phase II <input type="checkbox"/> Phase III <input type="checkbox"/> Phase IV <input type="checkbox"/> PMS <input type="checkbox"/> Bioequivalence <input checked="" type="checkbox"/> Others		
Director of IRB	Gil Hyun Kang		
<p>IRB of Asan Medical Center complies with the standards and regulations of ICH and KGCP. Investigators are authorized to proceed the study with an approval of IRB. In carrying out research, investigators should advance the study with an originally proposed protocol. Principal Investigator shall report to IRB immediately in case of Serious Adverse Event. Also, immediate actions include an occurrence of new information which might harm research applicants. The researcher should cooperate and submit research-related documents under the request of IRB. Also, investigators should follow the primary protocol as proposed except the circumstances which can endanger the participants enrolled in the research.</p>			
Submitted documents	<input checked="" type="checkbox"/> New protocol <input type="checkbox"/> Amendment <input type="checkbox"/> Suspended or Early-closed Report <input type="checkbox"/> Supplement (Conditional Approval) <input type="checkbox"/> Interim Report <input type="checkbox"/> Continued Review on Approved Protocol <input type="checkbox"/> Supplement (Re-review) <input type="checkbox"/> Result Report <input type="checkbox"/> Subject Wanted Ad <input type="checkbox"/> Final Report <input type="checkbox"/> Others:		
Results of Review	<input checked="" type="checkbox"/> Approval <input type="checkbox"/> Conditional Approval <input type="checkbox"/> Supplement (Conditional Approval) <input type="checkbox"/> Supplement (Re-review) <input type="checkbox"/> Rejection <input type="checkbox"/> Suspension or Reservation of Approved Clinical Trial		
Date of Approval	Nov 12, 2013	Continuing Review period	<input type="checkbox"/> 3 Month <input type="checkbox"/> 6 Month <input checked="" type="checkbox"/> 1 Year <input type="checkbox"/> Others
List of Submitted Materials	<ol style="list-style-type: none"> 1. Research Project Review Applications 2. Research Project protocol(Version 1.0) 3. Research Project Summation 4. Human derivatives research Informed Consent form(Version 2.0) 5. Case Report form(Version 1.0) 6. PI Curriculum vitae(Koon Hee Han) 7. bioethics Observance Covenant 8. GCP Certification(Jong Kyu Park, Hyun Il Seo, Yoon Mi Choi, Ji Eun Seo) 9. Research budget execution 		
Review Opinion	Approval. The Clinical Trial is started and one year later Investigator must submit the continuation report.		